^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ovarian Cancer
    Drug:pegylated liposomal doxorubicin (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Caelyx pegylated liposomal is indicated:...for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen…
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …the NCCN Panel added carboplatin/ liposomal doxorubicin as another first-line postopertaive intravenous option for patients with stages II to IV ovarian cancer; this regimen has a category 2A recommendation…
    Secondary therapy:
    carboplatin